Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
Tempus AI Inc Class A common stock TEM
News
Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Tempus to Report Third Quarter 2026 Financial Results on November 2
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Tempus Enters Multiyear Collaboration With Moderna, Merck Aimed at Commercializing Cancer Drug
Tempus Announces Multi-Year Collaboration with Moderna and Merck
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
CellCarta Adds Tempus to CDx Commercialization Lab Network
United States